Pricing

Merus BV (MRUS)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Sven A. Lundberg
Employees:
37
YALELAAN 62, 3584 CM UTRECHT, P7, 3584 CM
31 030 253 8800
Merus N.V. engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials. The company is also developing MCLA-158,158,145, and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available